Navigation Links
Sales of Antiretroviral Drugs for HIV Will Decrease Marginally Over the Next Decade, from an Estimated $13.4 Billion in 2012 to $13.1 Billion in 2022
Date:12/4/2013

BURLINGTON, Mass., Dec. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that major-market sales of antiretroviral (ARV) drugs for HIV will decrease marginally over the next decade, from an estimated $13.4 billion in 2012 to $13.1 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Human Immunodeficiency Virus (HIV) finds that the strongest factor constraining the HIV therapy market is the generic erosion of numerous key ARV drugs, such as efavirenz (Bristol-Myers Squibb's Sustiva, Merck/Banyu's Stocrin), tenofovir disoproxil fumarate [TDF] (Gilead/Japan Tobacco's Viread), atazanavir (Bristol-Myers Squibb's Reyataz), darunavir (Janssen's Prezista), emtricitabine/TDF (Gilead/Japan Tobacco's Truvada) and efavirenz/emtricitabine/TDF (Gilead/ Bristol-Myers Squibb's Atripla). Increasing availability of generics in cost-constrained markets will inhibit uptake of new, higher-priced agents and is responsible for decreased ARV sales in major pharmaceutical markets, particularly European markets where the impact of generic erosion will be the heaviest. Notably, all three active pharmaceutical agents in the 2012 sales leader, Gilead/ Bristol-Myers Squibb's single-tablet regimen (STR) Atripla will lose patent protection during the 2012 to 2022 forecast period, paving the way for generic STR prescribing in the major markets.

A key driver of sales growth in the HIV market is the increasing uptake of new, premium-priced agents, including integrase inhibitors and integrase inhibitor-based STRs. Diagnosis will also increase owing to broadening screening efforts and an expansion of the treatment-eligible population as a result of treatment guidelines urging treatment for HIV patients irrespective of CD4 cell levels, particularly in the United States.

The findings also reveal that, of the emerging therapies, the recently launched integrase inhibitor dolutegravir (ViiV's Tivicay) is best poised for commercial success during the 2012-2022 forecast period. ViiV is already marketing dolutegravir as a stand-alone product that can be used with different NRTI backbone regimens in the United States and has submitted regulatory filings to the EMA to support this usage.

"Uptake of dolutegravir will be somewhat constrained by the availability of generics for heavily prescribed, currently marketed ARV drugs such as Atripla and Gilead's newly available integrase inhibitor- based STR Stribild," said Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D. "Nevertheless, dolutegravir's strong clinical profile will enable this agent to achieve blockbuster status as both a stand-alone agent and as a component of the recently filed 572-Trii STR."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
2. InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
3. Radiation Therapy Equipment - Global Strategic Business Report 2012-2018 - Replacement Sales Spur Global Radiotherapy Market
4. Technology & Innovation Transforming Pharmaceutical Sales Training Programs
5. TCS Named a Global Leader in IDC MarketScape: Worldwide Life Science Sales & Marketing ITO 2013 Vendor Assessment by IDC Health Insights
6. Alpinion Medical Systems Appoints Lyle Mussman to Lead U.S. Ultrasound Sales
7. Richard Wolf USA And MAQUET Launch OR Integration Sales Partnership
8. Beat the Rush & Avoid the Crowds with CVS/pharmacy Black Friday Sales Event
9. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
10. Creekridge Capital Grows Healthcare Sales Team
11. Skyline Medical Appoints Stephen Zastrow as Senior Vice President of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):